- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Results From the STEP Trial in China
A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.
EP: 1.An Overview of the FIGARO-DKD Trial Design
EP: 2.Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD
EP: 3.An Overview of the FIDELITY Pooled Analysis Design
EP: 4.Results From the FIDELITY Pooled Analysis
EP: 5.Practical Implications of the FIDELITY Pooled Analysis
EP: 6.Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors
EP: 7.Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF
EP: 8.Results From the EMPEROR-Pooled Analysis
EP: 9.Unmet Needs in the Management of Heart Failure
EP: 10.Results From the STEP Trial in China
Transcript:
Rajiv Agarwal, MD, MS: One of the noteworthy trials to me was STEP, which was a large trial of more than 8000 patients in China between the ages of 60 and 80, randomized to 2 different blood pressure targets. The blood pressure target was 110 to 130 mm Hg and 130 to 150 mm Hg in a population of patients between 60 and 80 years old. They showed that cardiovascular outcomes are incredibly improved by treatment to a lower blood pressure target of 110 to 130 mm Hg. Well, it is a population of Chinese patients: 90% are Han Chinese, so it validates the results of the SPRINT trial to China.
Basically, what we found in the SPRINT trial in the United States is similarly what is being found in China. The goal here is that the broad application of blood pressure lowering to huge population segments, even when they are 60 years of age or older, can show benefit against cardiovascular disease down the road. That’s really noteworthy. In particular, I was impressed with hospitalization for heart failure, which was reduced by more than three-quarters by simply lowering blood pressure, and that’s really remarkable. People ought to pay attention to blood pressure, especially in people who are elderly.
Transcript edited for clarity.
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
